GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0% ...
For every 100 people contacted, 58 individuals never became active participants. This analysis made the conversion bottleneck visible, allowing the team to ask targeted questions about intake timing, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results